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Abstract 
 
Design, Synthesis, and Thermodynamic Evaluation of Peptidomimetic 
Ligands Binding to the Src SH2 Domain 
 
Christopher Alexander Farley, M.A.  
The University of Texas at Austin, 2018 
 
Supervisor:  Stephen F. Martin 
 
The ability to predict protein-ligand binding affinities is a difficult and elusive goal 
in the field of molecular recognition.  Models exist to predict binding energetics; however, 
they are not always capable of considering the incidental events in ligand-binding due to 
the tendency of the Gibbs free energy (ΔG°) to lack a correlation with enthalpy (ΔH°), 
entropy (ΔS°), or both.  Binding studies of various pYEEI-derived peptidomimetic ligands 
to the Src SH2 domain were evaluated to investigate the effects of structural changes on 
protein-ligand binding energetics.  The effect of preorganizing the pYEEI ligand into its 
binding conformation was analyzed by substituting the isoleucine residue with a 
conformationally constrained amino acid analog as well as a flexible analog.  Isothermal 
titration calorimetry studies were performed to assess the effects of ligand structure on 
protein-ligand binding energetics. 
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Chapter 1:  Thermodynamics of Protein-Ligand Interactions 
1.1 INTRODUCTION 
Among the major challenges in rational drug design and understanding molecular 
recognition processes in biological systems is how changes in the structure of small 
molecules affect their affinities for a protein target.  When a drug lead is discovered, efforts 
to improve the binding affinity to its target are undertaken by altering the molecular 
structure.  Critical to this endeavor is the ability to anticipate the binding energetics in 
protein-ligand interactions.  Predicting these interactions is complex, because one must 
consider a multitude of events that occur during binding, including protein dynamics, 
solvent, ligand, and protein reorganization.  
Models exist to predict binding energetics; however, they are not always capable 
of considering the incidental events in ligand-binding due to the tendency of Gibbs free 
energy (ΔG°) to lack a correlation with either enthalpy (ΔH°), entropy (ΔS°), or both.1-4  
There is a vast amount of data on protein-ligand binding; however, most of it is limited to 
binding affinity (Ka) with no corresponding information of the entropies and enthalpies of 
the binding event.3  Due to the lack of studies that investigate enthalpy and entropy of 
binding, there remains an uncertainty of how changes in ΔH° and ΔS° correlate with 
changes to ligand structure.  The inadequate tools available for predicting these energies 
have provided the impetus to evaluate the thermodynamic effects of introducing 
incremental structural changes to related ligands in protein binding interactions. 
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Numerous strategies to optimize binding affinity are employed to increase ΔH° and 
ΔS°. Increasing ΔH° most commonly includes alterations designed to increase noncovalent 
interactions.1,5-7  Strategies to optimize these stabilizing forces tend to lead to significant 
challenges due to the unfavorability of desolvating a polar group.  Furthermore, polar 
contacts in protein-ligand interactions, such as hydrogen bonding, tend to be highly 
dependent upon distance and angle, and even subtle perturbations that alter the orientation 
of polar groups can have dramatic effects on protein-ligand binding.8  Enhancing van der 
Waals contacts is conceivably easier in the sense that the strength of nonpolar contacts is 
determined by the distance between the nonpolar groups and the geometry of the contacts 
is not important.  Enhancing nonpolar contacts is not often used as a strategy to improve 
ΔH° of binding, but rather ΔS° and will be discussed in the next section. 
1.2 STRUCTURAL EFFECTS ON BINDING ENERGETICS 
One strategy to enhance ΔS° of binding is to preorganize the ligand into its 
biologically active conformation, which conventional wisdom dictates should reduce 
ligand entropy.5  Since ligands in solution do not predominantly exist in their bound 
conformation, they must reorganize to adopt the conformation in which they bind to their 
biological target.10  This reorganization is generally unfavorable because there is a decrease 
in entropy upon adopting a well-defined conformation.10-12  Global and local constraints 
have been utilized as methods to lock the molecule into its bound conformation.  The 
restriction of bond rotation, or the number of rotors, in the ligand reduces the entropy of 
the molecule in solution.13  However, minimizing the entropy term by preorganizing the 
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ligand in its biologically active conformation has not always translated into the predicted 
favorable changes in Gibbs free energy for ligand complexation with the protein.14-16 
 
 
Figure 1: Graphical representation of protein-ligand binding event. 
The top ligand is free to rotate while in solution, whereas that mobility is restricted in the 
constrained ligand. 
 
Another approach to enhancing binding affinity by improving ΔS° that has been 
used exploits the hydrophobic effect.  The hydrophobic effect is associated with the 
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tendency of nonpolar groups to aggregate in an aqueous environment, which in the context 
of protein-ligand interactions means that hydrophobic areas of a ligand will tend to be 
buried into hydrophobic regions of the protein upon binding.17,18  The solvation of polar 
and nonpolar groups by water leads to a loss of entropy, as the water molecules form an 
ordered network of hydrogen bonds to encapsulate the solute.  Upon ligand binding, the 
water molecules that solvate both the ligand as well as the protein are released to the bulk, 
which leads to an increase in degrees of freedom of water and thus a more favorable ΔS°.17  
However, since the proteins and ligands tend to be dynamic, the entropic component of 
this process is not the only thermodynamic parameter that can be considered in predicting 
binding affinities.18-19  Instead, if the structures of the ligand or protein are such that a 
hydrogen bonding network cannot be established in solution, the binding event can be 
enthalpically driven.20  The complex nature of the effects of hydrophobic interactions on 
protein-ligand binding, in particular on the discrete ΔH° and ΔS° components, remains an 
under-investigated topic of experimentation. 
 
Figure 2: Depiction of water solvation in protein-ligand interactions. 
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As previously noted, attempting to increase binding affinities of ligands to their 
targets is a challenge due to the unpredictability in how modifications to ligand structures 
will affect the binding enthalpies and entropies.  It has often been found that in efforts to 
optimize either ΔH° or ΔS° there is a compensatory effect in the other parameter such that 
the overall ΔG° of binding does not changes significantly.21  Enthalpy-entropy 
compensation is almost universally observed in protein-ligand interactions,22,23 prompting 
studies to determine whether this effect is an obligatory feature in such interactions.24  
Regardless of whether the enthalpy-entropy compensation is an inherent property of 
molecular recognition, the fact remains that preorganization is a proven strategy for 
enhancing affinity although the reasons why are not always well understood, and the 
benefits may be marginal or nonexistent.25 
1.3 ISOTHERMAL TITRATION CALORIMETRY 
Isothermal titration calorimetry (ITC) is a technique that allows one to determine 
thermodynamic parameters in a single experiment, including binding stoichiometry (n), Ka, 
ΔH°, ΔS°, and ΔG°.27,28  ITC is commonly used for its simple operation, accuracy, and 
ability to determine the aforementioned variables in a single experiment.  Traditionally, 
only Ka and ΔG° were easily determined, whereas elucidating ΔH° and ΔS° required 
multiple binding experiments at different temperatures in order to reliably calculate the 
values via a van’t Hoff analysis,27 using the equation: 
𝑙𝑛𝐾𝑎 =  − 
𝛥𝐻°
𝑅𝑇
+
𝛥𝑆°
𝑅
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where T is the temperature (Kelvin) and R is the ideal gas constant (1.985 cal/mol•K).  
Plotting ln(Ka) against T
-1 gives a straight line where the slope is ΔH°/R, and the y-intercept 
is ΔS°/R.  The analysis requires many experiments at variable temperatures in order to 
acquire results with good reliability.  Because Ka is temperature-dependent, even slight 
deviations in slope leads to errors in both entropy and enthalpy.  Due to the requirement of 
many repeated error-prone experiments, van’t Hoff analyses have fallen out of favor as a 
means to determine ΔS° and ΔH° with the rise in popularity of ITC. 
In an ITC experiment, solutions containing the ligand are injected to a sample cell 
containing a solution of protein.  After an injection, the instrument measures the power 
necessary to maintain the same temperature as a reference cell.  The measured power is 
plotted as a function of time, and then the area under the curve is integrated and plotted 
against the molar ratio between the ligand and protein.  From this second curve, ΔH° is 
determined by integrating the power required to maintain the same temperature throughout 
the experiment.  Binding affinity is the slope of the line tangent to the inflection point of 
the curve.  Given Ka and ΔH°, ΔG° and ΔS° can be calculated by the equations: 
 
ΔG° = -nRTln(Ka) 
ΔG° = ΔH° - TΔS° 
where temperature (T, Kelvin) is set in the experiment.  The rapid and operationally simple 
ITC experiments are an invaluable tool for examining energetics of binding events.  
Changes in binding affinity from one ligand to another to the same protein can be readily 
investigated by examining ΔS° and ΔH° of the binding event. 
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1.4 SRC SH2 DOMAIN 
The Martin group became interested in exploring the complexities of how ligand 
preorganization impacts protein-ligand interactions in the 1990s and initiated a research 
program to investigate the mysteries of the field.  Small ligands derived from peptides, or 
peptidomimetics, were selected as the chemical probes for the binding events because of 
their use as therapeutics in modern pharmaceuticals and due to the relative ease of 
modulating each amino acid residue on the ligand.29-30  The ability to incrementally alter 
the ligand structures is key to understanding the source of any changes in binding that may 
occur.  The initial thrust into this field of inquiry tested the binding of the Src SH2 domain 
(sarcoma homology 2 domain of the sarcoma tyrosine kinase protein) and a truncated 
version of its endogenous ligand. 
The first protein of interest for this new research program was Src, a tyrosine kinase 
involved in signaling pathways that cause bone resorption and it was identified as a 
potential target for the treatment of osteoporosis, sarcomas, and other diseases of the 
bone.31  As a result of the interest Src received from both academia and industry, there was 
a wealth of information available about the protein.  Among the most important things that 
were known about Src was that the SH2 domain bound with a 1:1 stoichiometry with its 
endogenous ligand, it had a well-defined binding site, and the protein does not undergo a 
significant structural change upon ligand binding.31,32  Seminal thermodynamic 
investigations were performed by Waksman and coworkers, who performed site 
mutagenesis studies on both the Src SH2 protein and the peptide ligand PQpYEEIPI.  Their 
investigations revealed that the pYEEI region of the ligand is the most important portion 
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for the binding event and engages in a so called “two-pronged plug two-holed socket” 
binding mode wherein the pY residue occupies a polar pocket and the Ile residue resides 
in a nonpolar pocket.33,34  Subsequent investigations by the Waksman group found that the 
pY residue is critical for binding in one pocket and found that the removal of a nonpolar 
side chain at the +3 site led to a much lower affinity binding event (pYEEI Ka = 5.5 x 10
6, 
pYEEG Ka = 2.6 x 10
5).35,36  They also replaced other residues of the ligand and found that 
replacing the two glutamate residues also led to a loss in binding affinity, but markedly less 
so than the replacement of pY or Ile. 
1.5 PREVIOUS MARTIN GROUP WORK 
1.51 Src SH2 
The Martin group was inspired by these reports and embarked on a study of 1,2,3-
trisubstituted cyclopropyl ligand derivatives of the native ligand for the Src SH2 with the 
intent of probing the effects of preorganizing the pY site in its binding conformation.  
Analysis of the Src SH2-ligand co-crystal structure indicated that the phosphotyrosine 
residue adopted a gauche conformation with respect to the ligand backbone, which could 
be approximated through the introduction of a cyclopropane ring.37  The so called “native” 
tetrapeptide pYEEI, constrained peptide mimic (cpYEEI), and flexible analog (fpYEEI) 
were synthesized and evaluated for binding in ITC studies.  The tetrapeptide subunit is the 
region of the endogenous ligand, the 11-mer peptide EPQpYEEIPIYL, that is in direct 
contact with the protein in the binding event.  The “reverse amide” moiety found in 
compound 2 was installed in order to maintain the same number of heavy atoms (in this 
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context, heavy atoms refer to any atom other than hydrogen) in order to accommodate the 
cyclopropane ring.  The reverse amide also maintains the relative position of the carbonyl 
group in the ligand so that changes to the structure were minimized.  Ligand 3 was prepared 
to serve as a flexible analog of 2 to account for altering ligand 1 to include the reversed 
amide functionality. 
 As seen in Table 1, the constrained ligand 2 had a more favorable ΔS° of binding 
compared to its flexible counterpart 3 and the native ligand 1, as hypothesized.  This was 
an exciting result because this was the first experiment that supported the long-standing 
adage that preorganization of ligands enhances entropy of binding.  Despite the enhanced 
ΔS°, the constrained ligand suffered an enthalpic penalty.  The enthalpy-entropy 
compensation that occurred led to a negligible difference in ΔG° between each of the 
ligands, although there was a slight benefit for 2 over its flexible counterpart, 3, and both 
over the native ligand. 
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Ligand Ka 
(M-1) 
ΔG° 
(kcal mol-1) 
ΔH° 
(kcal mol-1) 
-TΔS° 
(kcal mol-1) 
1 4.1 (± 0.1) 106 -9.01 ± 0.01 -6.06 ± 0.05 -2.95 ± 0.07 
2 1.0 (± 0.1) 107 -9.55 ± 0.07 -5.91 ± 0.04 -3.64 ± 0.13 
3 1.7 (± 0.1) 107 -9.80 ± 0.20 -7.33 ± 0.03 -2.47 ± 0.20 
Table 1: Binding data of ligands 1-3 binding to Src SH2 domain.37 
  
In an attempt to discover the source of the enthalpic compensation that was 
observed in this experiment, the Martin group turned to X-ray crystallographic studies to 
compare the structures of each of the modified ligands bound to the protein to the bound 
native ligand (Src SH2-1).  The crystal structure of the Src SH2 complex was compared to 
the Src-bound 11-mer peptide EPQpYEEIPIYL, which as previously mentioned is the 
endogenous ligand that binds to the Src SH2 domain.  Few structural differences were 
discovered in comparing the crystal structures of the truncated tetrapeptide to the longer 
peptide in the binding region, which validated the choice to use the synthetically simpler 
tetrameric peptide instead of the 11-mer in the studies that were to follow.33  Comparing 
the X-ray crystal structures of bound ligand 1 to bound ligand 2 revealed only minor 
differences in the binding conformations at the pY site and the pY+3 site (Figure 3A); these 
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two sites, as previously mentioned, are the sources of nearly all the binding energy.  There 
do exist differences in conformation at the pY+1 and pY+2 sites, however, while the 
differences were spatially significant they were determined not to be energetically 
consequential.  The variance in positions of both glutamate residues within asymmetric 
units of the crystal structures of a protein-ligand complex indicated that variations between 
different protein-ligand complexes were within the margins of error.36,37  Meaningful 
structural differences emerged upon comparing the flexible ligand, 3, to ligands 1 and 2, 
most notably at the pY site (Figure 3B, 3C).  The pY residue of 3 had a different orientation 
of both the methyl amide as well as the phenol phosphate group of the amino acid.  The 
amide nitrogen of 3 was able to engage in an intramolecular water-bridged hydrogen bond 
with the phosphate group, an interaction not observed in 1 (Figure 3B) and geometrically 
unattainable in ligand 2 due to the restrictive cyclopropane (Figure 3C).  This new 
interaction coincided with a loss of the hydrogen bond between the oxygen atom of the 
carbonyl group of the amide and the protein, though it also gained a water-mediated contact 
with the protein.   
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Figure 3:  X-ray crystal structures of ligands 1-3 bound to Src SH2 domain.  
A) Overlay of both poses of pYEEI complexes in the asymmetric unit (yellow and green) 
with both poses of constrained ligand 2 complexes in the asymmetric unit (pink and 
purple). B) Overlay of both poses of pYEEI complexes in the asymmetric unit (yellow and 
green) with flexible ligand 3 complexes in the asymmetric unit (blue). C) Overlay of both 
poses of ligand 2 complexes in the asymmetric unit with ligand 3 complexes in the 
asymmetric unit.38 
Although X-ray crystallography is an invaluable tool for examining protein-ligand 
interactions, it is not without limitations.  Protein-ligand interactions occur in solution; 
therefore, a solid state structural analysis will invariably lack information about the 
dynamic process.  That subtle differences between the crystal structures of 1 and 2 could 
correspond to significantly different binding thermodynamics were puzzling and warranted 
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further investigation.  Accordingly, Martin and Post examined the protein structures using 
nuclear magnetic resonance (NMR) and molecular dynamics (MD) studies.39  In the 1H-
15N HSQC experiments, the Src SH2-ligand complexes were examined for chemical shift 
perturbations (CSPs) and chemical shift differences (CSDs).  CSPs are the changes 
observed in Src SH2 amide N-H resonances upon complexation of the ligand to the protein, 
and CSDs are the differences in CSP magnitudes between each protein-ligand complex and 
the apo-protein (ie, protein with no bound ligand).  These experiments showed that 
significant CSPs occurred at the residues in the phosphotyrosine binding site.  The CSPs 
showed that there was an increase of deshielding effects, indicating altered hydrogen 
bonding interactions.39,40   
Figure 4 illustrates a stark difference in the chemical environments of the E178 and 
R175 residues in the Src SH2 binding site in the different protein-ligand complexes.  The 
binding of flexible ligand 3 to the protein led to the greatest chemical shift of the E178 and 
R175 protons as compared to the apo protein, followed by the native ligand 1, and 
constrained ligand 2.  These CSDs correlated with the observed trends of ΔH° from ITC 
experiments:  The Src SH2-3 complex had the strongest CSD as well as the most favorable 
ΔH°, followed by the Src SH2-1, and then the Src SH2-2 complexes, the last of which had 
the smallest CSD and the least favorable ΔH°.  This trend indicates that the hydrogen 
bonding interactions are strongest in the flexible ligand, and weakest in the constrained 
ligand, consistent with the enthalpic cost that was observed in the ITC experiments.19   
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A)  
B)  
Figure 4:  NMR studies of ligands 1-3 binding to Src SH2 domain. 
A)  1H-15N HSQC of apo-Src SH2 (cyan), ligand 1-Src SH2 adduct (yellow), ligand 2-Src 
SH2 adduct (red), ligand 3-Src SH2 adduct. B) Diagram of protein-ligand binding 
interactions at the pY-site of Src SH2.39 
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1.52 Grb2 SH2 Domain 
ITC experiments analogous to those performed on Src SH2 were carried out on 
another model protein, the SH2 domain of the growth receptor binding protein 2, or Grb2 
SH2.41   The Grb2 SH2 domain is an adapter protein responsible for cell proliferation and 
differentiation via the Ras pathway, stimulating interest in Grb2 SH2 as an anticancer drug 
target.41,42  Ligands 4-15 were prepared as truncated versions of the endogenous ligand and 
evaluated in the same manner as the ITC studies on ligands 1-3.  There was an enhancement 
of Ka and ΔG° in the constrained ligands, but this was accompanied by an unexpected less 
favorable ΔS°.  The enhanced ΔG° was a result of the more negative ΔH° values 
overpowering the relatively unfavorable entropic component in the constrained molecules. 
To elucidate the source of the confounding thermodynamic parameters, X-ray 
crystal structures of the protein-ligand complexes were analyzed.  Though both the flexible 
and constrained analogs bound in nearly identical conformations, the constrained ligands 
appeared to be involved in more direct polar contacts, which correlated with a more 
favorable ΔH° of binding.  Complicating the matter, however, was that the flexible ligands 
bound to the protein with more water-mediated contacts such that the number of total 
contacts was about the same as the constrained ligands.  These studies indicate that despite 
thermodynamic analyses and X-ray crystal structures to characterize binding events, there 
is a significant lack of understanding of protein-ligand interactions, especially the 
involvement of water in establishing polar contacts between the ligand and protein. 
 To shed light on the unexpected thermodynamic consequence between constraining 
the pY component of the ligand and its binding to the two different proteins, computational 
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studies were performed by collaboration with the Ren group on three sets of constrained 
and flexible analogs: Ligands 4 and 5, ligands 6 and 7, and ligands 10 and 11.43  One major 
finding from these molecular dynamics simulations was that a significant portion of the 
solution-state flexible ligand appeared to be stabilized by an intramolecular hydrogen bond 
between the phosphate group and the two amide groups of asparagine.  The constrained 
ligands were not able to adopt a conformation that permitted intramolecular hydrogen 
bonding, and thus were calculated to have higher solution state entropy as compared to the 
flexible ligand.  It may appear counterintuitive for the flexible ligand to be more 
preorganized, because the solution state conformation differs from the binding 
conformation to a large degree.  Bear in mind that since entropy is a state function (ie, the 
path by which a system converts from one state to another does not matter), the relatively 
highly-ordered solution state of the flexible ligands as compared to the constrained ligands 
therefore leads to a lesser differential of entropy between the solution and the ordered 
bound states, even though the bound conformation of the flexible ligand completely 
differed from the preferred solution-state conformation. 
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Figure 5:  MD-predicted solution state structures for ligands 4 and 5. 
Left: MD simulation of ligand 4 in solution, transparent conformation from crystal 
structure; Right: MD simulation of 5 in solution with macromolecular hydrogen bonds 
shown, transparent conformation from crystal structure. 
 
The ITC studies on modifying the ligands at the pY unit resulted in different 
thermodynamic profiles between the Src SH2 and Grb2 SH2 domains.  This is not 
completely unexpected given that the major stabilizing forces at the pY-binding site are 
hydrogen bonds, which are highly dependent on both distance and angle between the donor 
and acceptor.  A modification to this residue could have amplified and unpredictable 
thermodynamic consequences, and these examples provided two opposite results wherein 
the constrained pYEEI ligand bound with a more favorable ΔS° of binding to Src SH2 but 
the constrained pYVN ligand bound with a more favorable ΔH° of binding to Grb2 SH2.   
In addition to evaluating the effects of ligand preorganization, the Martin group has 
also examined the effects of increasing hydrophobic surface area upon energetics in 
protein-ligand interactions.  As noted earlier, increasing hydrophobic surface area is a tactic 
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that is normally used to enhance Ka by making binding more entropically favorable.
 44  
Ligands 16-23 were prepared with a straight-chain alkyl series 16-19 of pseudopeptides as 
well as a cyclic alkyl series 20-23.   
In general, for the ligands 16-19 there was little difference between the Ka and ΔG° 
values as chain length increased from ethyl to n-pentyl.  There does appear to be a slight 
benefit to enthalpy with a concomitant less favorable entropy for ligands 18 and 19, the 
ligands with n-butyl and n-pentyl as the R groups for the pY+1 amino acids; however, 
those values fall at the outer bounds of the margin of error.  It was determined by X-ray 
crystal structure analysis that ligands 18 and 19 make more van der Waals contacts with 
the protein than ligands 16 and 17, leading to a more favorable ΔH° of binding.  The less 
favorable ΔS° of binding may arise from the number of rotatable bonds being greater for 
ligands 18 and 19 than in the ligands with shorter R group chain lengths.  Recall that 
preorganization of ligands by restricting rotors is hypothesized to lead to a more favorable 
entropy of binding. 
There exists a clear trend of increasingly favorable Ka’s and ΔG°s as cycloalkane 
size increases from cyclopropyl to cyclohexyl for ligands 20-22.  Interestingly, this trend 
was driven by a more favorable ΔH° of binding and not ΔS° of binding.  As mentioned in 
section 1.2, the general hypothesis is that increasing nonpolar surface area leads to a more 
favorable ΔS° of binding due to the release of water molecules solvating the protein and 
ligand to the bulk.  The studies indicated that there was no correlation of the heat of 
solvation for the ligands with the increase in hydrophobic surface area, nor was there a 
correlation between the number of water molecules at the protein-ligand interface and the 
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entropy of binding.  This study again highlights the difficulties in understanding the role 
of structure on the energetics of protein-ligand interactions and the need for more studies 
on this phenomenon in order to better predict the effects of structural changes on protein-
ligand binding. 
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Ligand Ka 
(M-1) 
ΔG° 
(kcal mol-1) 
ΔH° 
(kcal mol-1) 
ΔS° 
(cal mol-1) 
4 2.8 (± 0.02) 106 -8.8 ± 0.02 -7.9 ± 0.29 3.0 ± 0.30 
5 4.5 (± 0.12) 105 -7.7 ± 0.02 -5.4 ± 0.14 7.9 ± 0.22 
6 2.1 (± 0.08) 106 -8.6 ± 0.02 -8.3 ± 0.30 1.3 ± 0.30 
7 4.1 (± 0.15) 105 -7.7 ± 0.02 -5.5 ± 0.20 7.4 ± 0.30 
8 7.1 (± 0.27) 105 -8.0 ± 0.02 -6.0 ± 0.22 6.6 ± 0.30 
9 1.7 (± 0.06) 105 -7.1 ± 0.02 -4.6 ± 0.17 8.6 ± 0.30 
10 1.2 (± 0.06) 106 -8.3 ± 0.01 -9.8 ± 0.20 -5.2 ± 0.18 
11 5.6 (± 0.15) 105 -7.8 ± 0.02 -8.7 ± 0.23 -2.8 ± 0.22 
12 3.6 (± 0.10) 105 -7.6 ± 0.02 -10.3 ± 0.27 -9.0 ± 0.22 
13 3.0 (± 0.08) 105 -7.5 ± 0.02 -8.8 ± 0.23 -4.3 ± 0.22 
14 5.5 (± 0.15) 105 -7.8 ± 0.02 -9.2 ± 0.24 -4.6 ± 0.22 
15 9.8 (± 0.23) 104 -6.8 ± 0.02 -7.7 ± 0.20 -3.0 ± 0.21 
Table 2: Binding data for ligands 4-15 binding to Grb2 SH2 domain.41 
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Ligand Ka 
(M-1) 
ΔG° 
(kcal mol-1) 
ΔH° 
(kcal mol-1) 
-TΔS° 
(kcal mol-1) 
16 8.6 (± 0.20) 105 -8.1 ± 0.1 -6.8 ± 0.5 -1.3 ± 0.1 
17 7.6 (± 1.0) 105 -8.0 ± 0.1 -6.7 ± 0.5 -1.3 ± 0.3 
18 8.4 (± 0.60) 105 -8.1 ± 0.1 -7.3 ± 0.3 -0.8 ± 0.2 
19 7.8 (± 0.60) 105 -8.0 ± 0.1 -7.2 ± 0.3 -0.8 ± 0.2 
20 1.6 (± 0.1) 105 -7.1 ± 0.1 -3.3 ± 0.3 -3.8 ± 0.1 
21 4.3 (± 0.4) 105 -7.7 ± 0.1 -5.4 ± 0.3 -2.3 ± 0.2 
22 16.1 (± 1.1) 105 -8.5 ± 0.1 -6.3 ± 0.4 -2.2 ± 0.2 
23 69.6 (± 12.) 105 -9.3 ± 0.1 -8.5 ± 0.4 -0.8 ± 0.4 
Table 3:  Binding data for ligands 16-23 binding to Grb2 SH2 domain.44 
1.6 SUMMARY AND CONCLUSIONS  
The Martin group has examined several different systems toward gaining a better 
understanding of the thermodynamics of binding and the implications of installing 
conformational constraints into small molecules.  Conventional wisdom would suggest that 
ligand preorganization should enhance binding affinity by reducing the entropic penalty 
upon binding.  The notion that enhancements in binding affinities of preorganized ligands 
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is primarily due to a more favorable entropy of binding has been tested by performing ITC 
experiments on how ligands bind to proteins, incrementally and systematically altering 
each ligand in order to examine the different thermodynamic profiles of each binding event.   
ITC experiments performed on the Src SH2 domain revealed that the hypothesis 
that preorganization of ligands leads to an enhancement of binding entropy holds for this 
system.37  Unexpectedly, however, the flexible counterparts to the constrained ligands were 
nearly equipotent in binding (ΔG° and Ka), because there was a lower ΔH° of binding for 
the constrained ligand compared to the flexible ligand.  The phenomenon of entropy-
enthalpy compensation remains an interesting, if at times frustrating, facet of the energetics 
of protein-ligand interactions.  In this example, introducing a conformational constraint at 
a residue that was involved in hydrogen bonding interactions with the protein was found 
to have a detrimental effect on ΔH° of binding to compensate for the enhancement to ΔS° 
of binding.  The flexible analog was able to engage in stronger hydrogen bonding 
interactions between the phosphotyrosyl side chain of the ligand and the protein, which led 
to a more favorable ΔH° of binding. 
Analogous binding studies performed on the Grb2 SH2 domain returned the 
confounding result that conformationally constrained ligands actually bound with a less 
favorable ΔS° of binding compared to their flexible controls.41  These results were maybe 
a result of the flexible analog having a lower solution state entropy than the constrained 
ligand, which MD studies suggest is due to the presence of stabilizing macrocyclic 
hydrogen bonding interactions within the ligand.43  The ligand that was preorganized into 
its binding conformation therefore was actually less “preorganized” than the ligand 
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intended to have more degrees of freedom.  This finding was astonishing in that there was 
evidence that constraining a small molecule into its binding conformation could actually 
be less preorganized than a structurally similar molecule that adopted a solution state 
conformation that did not resemble the binding conformation at all. 
Other studies on the Grb2 SH2 system revealed that increasing hydrophobic surface 
area enhanced binding affinity due to more favorable enthalpies of binding instead of 
entropies of binding, contrary to what was predicted.44  There was a correlation of more 
favorable binding affinities within the ligand series as straight chain alkyl R groups were 
lengthened from ethyl to pentyl, and as aliphatic ring sizes increased from cyclopropyl to 
cyclohexyl.  The enhancement in binding affinity was found to be due to a more favorable 
ΔH° of binding, where the ligands with more hydrophobic surface area engaged in more 
nonpolar contacts.  It was predicted that the enhancement in binding affinity would be due 
to a more favorable ΔS° of binding, which would be a result of desolvation of the ligand 
and protein to release solvating water molecules to the bulk.  These results show that 
predicting binding thermodynamics is remarkably difficult, and there remains a great deal 
to be understood about protein-ligand interactions before predictions can be considered 
useful. 
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Chapter 2:  Design and synthesis of Ligands for the Src SH2 Domain 
2.1 INTRODUCTION 
The root cause of the observed entropy/enthalpy compensation in the Src studies 
was hypothesized as being at least in part due to be the alteration of the highly sensitive 
hydrogen bonds between the pY residue and its binding pocket.  This observation led us to 
query whether preorganizing pYEEI at the pY+3 site would confer favorable binding 
entropy with either lessened or no enthalpic penalty.  Isoleucine, which is the residue at the 
pY+3 site, bears a hydrocarbon side chain that engages in nonpolar contacts with the 
protein.  Waksman found that substituting Ile for other amino acid residues led to a decrease 
in binding affinity.36  Interestingly, Ile had a less favorable ΔS° of binding, but had a strong 
ΔH° of binding relative to the other nonpolar amino acid residues.  A highly favorable 
enthalpy of binding is suggestive of strong nonpolar contacts and given the marked 
decrease in potency of other amino acids at the pY+3 site, the authors concluded that an 
Ile residue at the pY+3 site engaged in optimal nonpolar contacts, suggesting the binding 
site is highly ordered.  This conclusion was unusual, since unlike polar binding sites, 
binding contacts in hydrophobic sites are distance dependent but not angle dependent. 
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Ligand Ka (M-1) ΔG° 
(kcal mol-1) 
ΔH° 
(kcal mol-1) 
-TΔS° 
(kcal mol-1) 
pYEEI 5.5 (±0.7) 106 -9.2 ± 0.1 -7.7 ± 0.2 -1.5 ± 0.2 
pYEEL 2.3 (±0.4) 106 -8.7 ± 0.1 -5.6 ± 0.4 -3.1 ± 0.4 
pYEEV 2.2 (±0.3) 106 -8.7 ± 0.1 -5.4 ± 0.2 -3.3 ± 0.2 
pYEEA 5.7 (±2.0) 105 -7.8 ± 0.2 -5.1 ± 0.4 -2.7 ± 0.4 
pYEEG 2.6 (±0.1) 105 -7.4 ± 0.1 -3.6 ± 0.1 -3.8 ± 0.1 
Table 4:  Binding data for octapeptides Ac-PQpYEEXIPI binding to Src SH2 domain.36 
2.2 DESIGN OF SRC SH2 LIGANDS 
Given the relative importance and high degree of residue specificity of the pY+3 
site for the pYEEI-Src SH2 binding event, we were intrigued by the possibility of 
preorganizing pYEEI at its pY+3 site.  The specificity required of the pY+3 residue of the 
ligand to achieve potent binding with Src SH2 suggested that introducing a conformational 
constraint might enhance ΔS° of binding, perhaps to a significant extent.  However, since 
the binding pocket is nonpolar, we did not expect to see as significant of a loss of enthalpy 
as was observed in the prior work with Src SH2 ligands.37  The less favorable ΔH° of 
binding with conformational constraints at the pY site was at least in part due to disruption 
of the hydrogen bonds between the phosphotyrosine and the binding pocket.  Hydrogen 
bonds, as stated earlier, are highly dependent on both distance and angle for strong 
interactions.  By contrast, nonpolar contacts characterize binding in the pY+3 site, which 
are not angle dependent, but rely only on distance.  Assuming the structure of the ligand 
with the conformational constraint at the pY+3 site places the R group in a conformation 
that closely mimics the pYEEI ligand, the nonpolar contacts should not weaken much at 
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all.  To this end, we decided to synthesize the constrained ligand 24 and its flexible 
counterpart 25.  Additional studies were planned for studying the constrained ligand 26 
and the flexible control 27, which will further enhance our understanding of the results of 
constraining the pYEEI ligand at the pY+3 site.38,45 
 
 
Ligand 24 was designed with the goal of constraining the ethyl group of Ile into its 
binding conformation in ligand 1 using a cyclopropane ring.  The design maintains the 
same number of heavy atoms as 1, but the methyl group of 1 becomes the methylene group 
of 24.  This presents one key difference between ligands 24 and 1; the methylene group of 
the cyclopropane does not reside in the same relative space as the methyl group does in Ile.  
Ligand 27 was designed to permit bond rotation about all carbon-carbon bonds.  The 
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flexible analog will also probe the effect of removing the methyl group from Ile in 1.  The 
methyl group of Ile in 1 engages in nonpolar contacts with the protein which will not be 
available for 25 to engage in, adding to the relevance of 24 as an analog. 
2.3 SYNTHESIS OF CONSTRAINED LIGAND 
 The synthesis of 24 commenced with the preparation of the constrained cyclopropyl 
amino acid 28.  This amino acid is a natural product and has been made several times,46 
but the route reported by Ortuño was selected as the protocol for our synthesis due to its 
brevity and overall high-yielding steps that confer excellent levels of diastereoselectivity.46  
It should be noted that Schöllkopf also completed the synthesis of 28 by a different route, 
but a colleague was experiencing difficulties replicating the reported procedure. 47  Hence, 
we decided to explore the Ortuño route to 28, but we discovered it too was not without 
problems.   
 
One of the key steps for preparing allo-coronamic acid (28) in the Ortuño synthesis 
was a Horner-Wadsworth Emmons (HWE) reaction between (D)-glyceraldehyde acetonide 
29 and the phosphonate 32 (Scheme 1).  Ortuño prepared known compound 32 in three 
steps following literature precedent (Scheme 2).48,49  The resulting olefinic amino acid 40 
was treated with diazomethane and light to introduce the cyclopropane with complete 
diastereomeric control in quantitative yield to provide cyclopropyl amino acid 41 (Scheme 
1).  The acetonide was deprotected to reveal the diol, which was then converted to the vinyl 
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cyclopropane 45 over three steps in good yield.  Hydrogenation of the vinylcyclopropane 
provided the methyl ester of allo-coronamic acid, which we would use to begin the 
sequence of peptide couplings to furnish tetrapeptide 24. 
 
 
Scheme 1: Ortuño route to allo-coronamic acid (28).46 
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Scheme 2: Ortuño protocol for preparing α-phosphonoglycinate 32.46 
 
Though commercially available, D-glyceraldehyde acetonide (29) is somewhat 
costly, but it is readily prepared from inexpensive D-mannitol (30) (Scheme 3).  This 
known two-step process was achieved by first selectively protecting 30 as the 1,2;5,6 O-
isopropylidine acetal 31,50 which afforded 29 upon oxidative cleavage in 59% yield over 
two steps.51   
 
Scheme 3: Synthesis of glyceraldehyde acetonide 29. 
 
Although the synthesis of 29 was achieved without complication, the preparation 
of the phosphonate 32 proved more troublesome.  Ortuño prepared the phosphonate via an 
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Arbuzov reaction of trimethyl phosphite with the α-haloglycinate 38.  Toward the 
preparation of 32, the α-hydroxy glycine 34 was first formed from the reaction of benzyl 
carbamate with glyoxylic acid (33) (Scheme 4).52  Conversion of 34 to the methyl ester 35 
was achieved under acidic conditions in methanol.  We were dissatisfied with the low yield 
to give 34, so a different protocol to form the phosphonate 32 was investigated. 
 
  
Scheme 4: Abandoned partial route to phosphonate 32. 
 
Instead of constructing the methyl ester from a carboxylic acid, we turned to 
forming methyl glyoxylate (37) through periodic acid-mediated oxidative cleavage of 
dimethyl tartrate 36 (Scheme 5).53  Methyl glyoxylate (37) was allowed to react with benzyl 
carbamate in the presence of acetyl chloride and a catalytic amount of acetic acid to furnish 
the α-chloroglycinate 38.54  It had been reported that 38 is isolable upon evaporation of the 
solvent,54 but it readily undergoes hydrolysis on silica gel.  Accordingly, we decided to 
isolate 38 and use it in the following reaction without purification.  Unfortunately, a 
mixture (50:50) of α-chloro- and α-acetoxyglycinates 38 and 39 (determined by 1H NMR) 
was produced.  Due to the difficulty of separating 38 and 39, the mixture was treated with 
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phosphorus trichloride to effect complete conversion to the α-chloroglycinate 38 in 62% 
yield.   
 
Scheme 5:  Synthesis of phosphonate 32. 
 
Frustrated by the inability to isolate 38 cleanly and efficiently, we hypothesized 
that the introduction of trimethyl phosphite to the reaction could initiate the Arbuzov 
reaction without isolating the glycinate 38.  We modified the reaction conditions for the 
formation of 38 by using toluene instead of dichloromethane in order to accommodate the 
higher reaction temperatures required for the Arbuzov reaction.  Benzyl carbamate, methyl 
glyoxylate, and AcCl were stirred overnight according to the original report to prepare 38, 
and then P(OMe)3 was added, and the mixture was stirred for 3 h.  To our delight, 
phosphonate 32 was formed by this 4-component-one-pot reaction in 60% yield (Scheme 
6).54,55 
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Scheme 6:  One-pot reaction from 37 to 32. 
 
With both 29 and 32 in hand, the HWE reaction proceeded smoothly to give 40 
(Scheme 7), albeit in only 56% yield.46,49  Ortuño obtained 40 in 92% yield and 95:5 Z:E 
ratio.  While we were able to reproduce the high stereocontrol, the reported yield could not 
be replicated.   
 
Scheme 7: HWE reaction between 29 and 32. 
 
 
Figure 6: Felkin-Ahn model of 40. 
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The olefinic amino acid 40 is the substrate for a cyclopropanation reaction, which 
Ortuño accomplished via a [2+3] cycloaddition between the olefin in 40 and diazomethane 
followed by extrusion of dinitrogen.  In the interest in not using such a dangerous reagent, 
alternative methods to cyclopropanate the olefin were explored.  At this juncture, we faced 
perhaps the greatest question of our modified synthesis:  What is the facial selectivity of 
alternative cyclopropanation methods?  Ortuño achieved high diastereoselectivity (95:5 
Z:E) and invoked the Felkin-Anh model (e.g., 40’) of the transition state to rationalize the 
observed outcome.  Based upon this model, we had reason to believe that other 
cyclopropanation reactions would also be diastereoselective (Figure 6).  One alternative 
that was considered included using the less-explosive (trimethylsilyl)diazomethane in the 
same manner.  This reagent is not particularly desirable, as it is highly toxic and the 
tendency to explode is merely mitigated compared to diazomethane.  Furthermore, a 
reaction with (trimethylsilyl)diazomethane would necessitate an additional step to remove 
the TMS group on the resulting cyclopropane ring.  A Corey-Chaykovsky 
cyclopropanation was also briefly considered, but such cyclopropanations typically require 
good Michael acceptors; the partial enamine character of 40 gave us pause.  We then 
surmised that a Simmons-Smith reaction (or one of the several modifications) might serve 
as an effective reaction and was explored first. 
The Simmons-Smith reaction has been known for several decades, and it may be 
applied to a wide variety of alkenes.  Moreover, the reaction is chemoselective and has 
high functional group tolerance.56  A particularly attractive feature of the Simmons-Smith 
reaction is that the reaction can be rendered stereoselective through the use of a directing 
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group like an allylic alcohol or ether, the latter of which is a moiety present in 40.56  We 
anticipated high stereoselectivity since the most stable conformation of the substrate placed 
the allylic oxygen in position to direct the active zinc species to the appropriate face (Figure 
6).   
The original Simmons-Smith reaction employs a Zn/Cu couple, which is 
troublesome to prepare, provides inconsistent results, and is often lower-yielding than some 
of the modern modifications.56  The Furukawa58 and the Denmark modifications59 are two 
of the most commonly utilized variations.  Both of these reactions employ Et2Zn as the 
zinc source but differ in the carbenoid source; the Furukawa modification uses CH2I2 
whereas Denmark conditions use CH2ICl.  There are also other alternatives wherein the 
reactivity of the zinc carbenoid is modulated by the identity of the carbenoid.  For example, 
the Shi modification employs a trifluoromethylacyl carbenoid that is highly reactive,60 and 
the Charette modification uses a di-n-butylphosphonate-derived organozinc species that is 
less reactive.61  We opted to test the Furukawa conditions first, due to the availability of 
diiodomethane and the success of this particular modification in related substrates.56,62  
Indeed, the cyclopropanation using the Furukawa modification provided 41 in 90% yield 
and >20:1 dr (Scheme 8).62  The 1H NMR spectrum of 41 matched the correct diastereomer 
as reported in the literature.46  Deprotection of the acetonide 41 to the diol 42 proceeded 
smoothly in 98% yield. 
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Scheme 8: Cyclopropanation and acetonide hydrolysis. 
 
We initially planned to elaborate the diol 42 via a Corey-Winter olefination.46  To 
this end, 42 was quantitatively converted to the thiocarbonate 43 with 1,1-
thiocarbonyldiimidazole (TCDI) (Scheme 9). 
 
Scheme 9: Conversion of the diol moiety to the saturated alkyl chain. 
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The thiocarbonate 43 was stirred with the Corey-Hopkins reagent 44,63 a phosphine 
that eliminates the thiocarbonate under milder conditions than the original Corey-Winter 
protocol.64  Unfortunately, the desired olefin 45 could not be isolated, and the 
inconvenience of using the air and moisture-sensitive TCDI and Corey-Hopkins reagent 
helped to persuade us to find a new approach to the elaboration of diol 42 to the amino acid 
28.  Radical-based deoxygenations were not explored since carbon-centered radicals 
adjacent to cyclopropane rings readily undergo ring-opening reactions, so we turned to a 
two-step oxidative cleavage and Wittig olefination procedure to convert 42 to 28.   
Diol 42 was subjected to a periodate-mediated oxidative cleavage to give the 
aldehyde 53 (Scheme 10).46  The aldehyde 53 was used directly without purification in the 
next reaction to avoid possible epimerization.  Olefination of 53 with the lithium ylide of 
methyl(triphenyl)phosphonium bromide gave varying yields (40-60%, two steps) of the 
vinylcyclopropane 45.  According to the protocol reported by Ortuño, the alkene moiety of 
45 could be reduced with concomitant removal of the Cbz protecting group in one 
operation by catalytic hydrogenation with Pearlman’s catalyst.  Unfortunately, we were not 
able to replicate this reduction, and none of the desired 28 could be identified.   
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Scheme 10:  Alternative protocol for the transformation of diol 42 to cyclopropyl amino 
acid 28. 
Due to the various problems with the Ortuño approach to 28, this route was 
abandoned in favor of the Schöllkopf approach.  The problems associated with reproducing 
the Schöllkopf approach were solved by a colleague during the exploration of the Ortuño 
route as an alternative strategy.  This route to 28 uses the eponymous “Schöllkopf 
auxiliary.”  This auxiliary is a protected cyclic dipeptide consisting of a bulky amino acid 
such as valine or t-butylglycine and glycine, which becomes the amino acid backbone of 
the desired compound.  Deprotonation of the glycine moiety and subsequent treatment with 
an electrophile is rendered diastereoselective by the chiral center of the valine moiety.  The 
newly synthesized enantioenriched amino acid can be liberated from the auxiliary by acidic 
hydrolysis. 
 
 38 
 
Figure 7:  Stereochemical model of Schöllkopf asymmetric amino acid synthesis. 
Depicted with D-valine as the auxiliary. 
 
 The synthesis of 28 following the procedure reported by Schöllkopf began with the 
protection of D-valine and subsequent coupling with ethyl glycinate to form 48 in 87% 
yield over two steps (Scheme 11).65  Heating the dipeptide 48 under reflux in 1,2-
dichlorobenzene gave the diketopiperazine 49 in 74% yield.  Alkylation of 49 with ethyl 
Meerwein’s salt provided the bislactim ether 50 in 77% yield, which was then deprotonated 
with n-BuLi and alkylated with 1,4-dichloro-trans-2-butene to give 51 in 55% yield.  
Reacting 51 with n-BuLi furnished the cyclopropyl spirocycle 52 via an intramolecular 
SN2’ reaction in 40% yield, and subsequent diimide reduction of the terminal olefin 
delivered 53 in 91% yield.  Acid promoted hydrolysis of 53 liberated the cyclopropyl amino 
acid ester 28 from valine ethyl ester. 
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Scheme 11:  Synthesis of the Schöllkopf auxiliary and formation of cyclopropyl amino 
acid 28. 
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Elaboration of amino acid 28 to the constrained ligand 24 began with coupling 28 
to the protected glutamate 54 to provide dipeptide 55 in 51% yield (Scheme 12).  An X-
ray crystal structure was obtained for this compound in order to confirm the absolute 
stereochemistry of the cyclopropyl amino acid (Figure 8).  Boc deprotection of the 
dipeptide 55 followed by peptide coupling with another protected glutamate 54 delivered 
the tripeptide 57 in 71% yield over two steps.  Boc deprotection of 57 followed by 
coupling with protected phosphotyrosine 59 provided the fully protected tetrapeptide 60.  
A global deprotection of 60 appeared unlikely given the presence of an ethyl ester among 
the relatively labile benzyl esters and benzyl carbamate.  Accordingly, the benzyl 
carboxylic esters, benzyl phosphate esters, and benzyl carbamate were removed by 
hydrogenolysis to provide 61, which was saponified and then acylated to provide the final 
ligand 24 (Scheme 13).  The final two steps proceeded in 17% yield after HPLC 
purification.   
 
Figure 8: X-ray crystal structure of dipeptide 55.  
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Scheme 12: Synthesis of tetrapeptide intermediate 60. 
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Scheme 13: Completion of constrained ligand synthesis. 
2.4 SYNTHESIS OF FLEXIBLE LIGAND 
 The synthesis of the flexible ligand 25 commenced with the Fischer esterification 
of commercially available L-norvaline (63) with benzyl alcohol (Scheme 14),68 as 
described by Dr. Amy Bonaparte.45  The p-toluenesulfonic acid salt of L-norvaline benzyl 
ester 64, which was isolated in 80% yield, was subjected to a peptide coupling with the 
protected glutamate 54 to provide the dipeptide 65 in 85% yield.  Following the quantitative 
deprotection of 65, amine 66 was subjected to another peptide coupling with 54 to furnish 
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the tripeptide 67 in 80% yield.  The tripeptide was deprotected to give 68, which was 
coupled with phosphotyrosine 59 to provide the protected tetrapeptide 69.  Following 
global deprotection by hydrogenolysis, the crude tetrapeptide 70 was acylated to afford the 
final ligand 25 (Scheme 15). 
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Scheme 14:  Synthesis of tetrapeptide intermediate 69. 
 45 
 
Scheme 15: Completion of flexible ligand synthesis. 
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2.5 ITC STUDIES 
 
Ligand Ka (M-1) ΔG° 
(kcal mol-1) 
ΔH° 
(kcal mol-1) 
TΔS° 
(kcal mol-1) 
1 (lit)37 4.1 (± 0.1) 106 -9.01 ± 0.01 -6.06 ± 0.05 -2.95 ± 0.07 
1 4.2 (± 0.3) 106 -9.03 ± 0.05 -5.15 ± 0.25 -3.89 ± 0.64 
24 1.5 x 106 -8.43 -5.30 -3.13 
25 4.0 (± 0.3) 106 -9.00 ± 0.05 -5.36 ± 0.34 -3.64 ± 0.66 
Table 5:  Binding data for ligands 1, 24, and 25 binding to Src SH2 domain. 
 
ITC studies were performed on ligands 24, 25, and compared to pYEEI (1).  We 
first performed binding studies of 1 with the Src SH2 domain.  We found that the Ka and 
ΔG° values were in good agreement with the previous report (Table 5),37 but there was a 
difference in ΔH° and ΔS° between the experiments.  It is not clear what caused the 
disparity in results, though there are a few possible reasons.  Since the original data were 
obtained over 15 years ago, the isothermal titration calorimeter had been replaced.  
Additionally, the instrument was malfunctioning and required changing titration conditions 
from the settings used in the original report to obtain reproducible data.  In particular, 
baseline noise from the instrument was an issue when the calorimeter stirred at the rate in 
which previous Martin group ITC experiments had been run.  The stir rate was lowered 
 47 
and the time between ligand injections to the protein was increased to ensure good mixing.  
There were also problems with baseline drift which required a lengthy delay (~1.5-2h) 
between the start of data collection and the first injection.  Both the baseline drift and 
background noise issues were alleviated when the power setting for the ITC was lowered.  
The power setting was within normal bounds prescribed by the instrument manual and 
should not have affected the values attained.  It is also noteworthy that the standard errors 
are larger for current experiments compared to the prior report, though they are acceptable.  
Despite all these changes, the data obtained were reproducible and the reported values are 
the average of triplicate trials for 1 and quadruplicate trials for 25. 
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Figure 9:  Example ITC trace of 1. 
Top: Raw data as heats of 
complexation (μcal/sec). 
Bottom:  Integrated ITC data as heats 
of binding per mol of ligand. 
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Figure 10:  Example ITC trace of 24. 
Top: Raw data as heats of 
complexation (μcal/sec). 
Bottom:  Integrated ITC data as heats 
of binding per mol of ligand. 
Figure 11:  Example ITC trace of 25. 
Top: Raw data as heats of 
complexation (μcal/sec). 
Bottom:  Integrated ITC data as heats 
of binding per mol of ligand. 
 49 
While it was worrisome that ΔH° and ΔS° values attained for 1 were not in close 
agreement with the prior report, even when considering the margins of error of the present 
binding experiments, we would still be able to test our hypothesis:  Does preorganizing the 
ligand at the pY+3 site enhance binding affinity over a non-modified ligand, and if so, is it 
due to a more favorable ΔS° of binding?   
 We first tested the flexible ligand 25 and found that it bound with a comparable Ka 
and ΔG° as 1, but it bound with a less favorable ΔS° and more favorable ΔH° (Table 5).  
The data did fall within the margins of error for both ligands, however.  Recall that pY+3 
mutagenesis studies by Waksman (Table 4) revealed that the pY+3 = Ile ligand bound with 
a significantly higher ΔH° than leucine, valine, alanine, and glycine residues, whereas it 
had a much less favorable ΔS° of binding.  Thus, it is surprising that we would observe a 
more favorable ΔH° of binding for ligand 25 accompanied by a less favorable entropic 
component.  Waksman proposed that the highly favorable ΔH° of binding for the isoleucyl 
ligand and relatively low corresponding ΔS° value indicated a strong specificity for Ile and 
that it maximized van der Waals contacts while other ligands apparently did not.  The 
norvaline residue of ligand 27 lacks a methyl group that isoleucine has, which is somewhat 
confounding considering the lack of a methyl group would be predicted to have fewer van 
der Waals contacts thereby have a less favorable enthalpy of binding.  What is interesting, 
though, is that 1 and 25 are equipotent and have similar ΔS° and ΔH° values of binding; in 
Waksman’s study altering pY+3 from isoleucine to other nonpolar amino acids he observed 
a twofold decrease in binding affinity when the isoleucine residue was converted to a 
leucine or valine residue.  It may be the case that a propyl group in the pY+3 side chain fits 
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intimately in the binding pocket, whereas an isobutyl group (leucine) is too large.  On the 
other hand, valine, with the comparatively smaller R group, is unable to occupy the binding 
pocket as deeply.  The β-branched methyl group of the valine side chain, however, is likely 
important to binding since the valyl and leucyl analogs of Waksman’s ligands were 
equipotent with each other and had similar entropies and enthalpies of binding.   
Our result with the norvaline residue implies that a straight chain occupying the 
binding pocket is more impactful on ΔH° of binding than the β-methyl moiety of 
isoleucine.  Perhaps the β-methyl group of isoleucine blocks the rest of the side chain from 
binding as deeply within the binding site as the norvaline residue.  If this characterization 
of the isoleucine methyl group as a steric block for binding is correct, then that could 
potentially rationalize the less favorable ΔS° of binding observed in ligand 25 wherein the 
closer association of the norvaline residue is more ordered by nature of having stronger 
van der Waals interactions. 
 Ligand 24 has only been tested once at the present time; accordingly, any discussion 
will naturally be limited by the lack of replication.  We found that 24 had a slightly lower 
Ka and ΔG° as compared to ligand 1, and like ligand 25 it bound with a more favorable 
ΔH° of binding and a less favorable ΔS° of binding than ligand 1 (Figure 7).  We were 
surprised that our hypothesis that ligand 24 would not only bind more strongly but have a 
less favorable entropy of binding was completely backwards.  It is worth noting that the 
predicted ground state conformation of 1 at the pY+3 site corresponds to the bound 
conformation of that residue.  In other words, the Ile group in 1 is already preorganized in 
its binding conformation in the solution state.  What is also striking is that 24 and 25 had 
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nearly the same ΔH° of binding; ligand 24 was less potent than 25 solely due to a less 
favorable ΔS° of binding. 
 The preorganized ligand 24 has the same number of carbon atoms as 1, but it has a 
methylene group instead of a methyl group on the side chain of the pY+3 residue.  The 
geometry of the cyclopropane invariably alters the position of the methylene group such 
that it does not approximate the methyl group of the isoleucine residue in 1.  As previously 
mentioned, it is possible that the β-branched methyl group is not very important for potent 
binding and that the presence of a non-branched alkyl chain that binds deeply within the 
binding pocket is more important.  Therefore, it might be the case that the cyclopropylethyl 
side chain can bind deeply within the nonpolar binding site since the β-methylene group in 
24 cannot be positioned where the β-methyl group of 1 resides.  The implications of this 
constraint on the conformation are unclear without structural data to study the ligand 
binding mode and the interactions in the complex. 
 We also know that ligand 24 is less potent than 25, solely due to a less favorable 
ΔS° of binding.  The obvious first conclusion would be that ligand 24 does not approximate 
the binding conformation of 25.  The key structural difference between 24 and 25 is that 
ligand 24 has an extra methylene group, which not only adds hydrophobic surface area, but 
restricts the degrees of freedom of the R group.  What is not clear is how that structural 
difference manifests in the binding conformations with the protein.  The rigidity imparted 
by this structural feature may force the constrained ligand to adopt a conformation in 
solution that does not resemble its binding conformation, and furthermore might restrict 
any bond rotations required for the ligand to adopt the binding conformation. 
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2.6 SUMMARY AND FUTURE DIRECTIONS 
 Predicting the thermodynamic effects of preorganizing ligands for protein binding 
by introducing conformational constraints is difficult and does not always lead to the 
expected results.  Herein we explored the effects of preorganizing the pYEEI ligand at the 
pY+3 site using a cyclopropane ring as a conformational constraint.  Previous Martin group 
reports revealed that constraining the pY residue of ligand 1 enhanced binding affinity to 
the Src SH2 domain through a more favorable ΔS° of binding, as predicted.  However, the 
more favorable ΔS° of binding was offset by a less favorable ΔH° of binding.  Since the 
pY binding pocket is characterized by hydrogen bonds, which are sensitive to distance and 
angle between polar contacts, even small perturbations in the conformations of the ligands 
resulted in significant changes to the thermodynamics of binding.  As mentioned in Section 
1.52, however, preorganizing the pY residue of the pYVN ligands for Grb2 SH2 domain 
binding led to a less favorable ΔS° of binding accompanied by a more favorable ΔH° of 
binding. 
 We designed ligands 24-27 to test our hypothesis that introducing a conformational 
constraint at the nonpolar pY+3 residue would enhance binding affinity through a more 
favorable ΔS° of binding as was observed with ligand 2 while mitigating the entropy-
enthalpy compensation since van der Waals contacts are only dependent on distance, not 
angle.  Ligand 25 was prepared in eight steps and ligand 24 was prepared in 16 steps.  
Intermediate 28, allo-coronamic acid, proved difficult to access.  Initial attempts to prepare 
28 following the procedure reported by Ortuño, was unsuccessful.  During attempts to 
overcome challenging steps in the Ortuño route, we developed a four-component-one-pot 
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protocol for preparing α-phosphonoglycinate 32 and avoided the use of diazomethane as a 
cyclopropanating reagent by employing a variant of the Simmons-Smith reaction.  Amino 
acid 28 was eventually prepared in eight steps using Schöllkopf’s procedure, which enabled 
the preparation of 24 in eight additional steps. 
 ITC studies revealed that the flexible analog 25 was equipotent with the “native” 
ligand 1, though 25 had a slightly more favorable ΔH° of binding that was offset by a less 
favorable ΔS° of binding.  This demonstrates another example of entropy-enthalpy 
compensation, yet it remains unclear what could be the cause of the difference in binding 
energetics.  The entropy and enthalpies of binding of those two ligands are within margins 
of error, however, so it is difficult to draw definitive conclusions about the differences 
between 1 and 25.  Constrained ligand 24 was less potent than both 25 and 1.  Surprisingly, 
ligand 24 had a less favorable ΔS° of binding than ligand 25, which is the opposite result 
we expected to observe.   
Structural analysis such as X-ray structures of the protein-ligand complexes will be 
valuable for contextualizing the ITC results with the binding conformations.  
Understanding why changing the pY+3 residue from isoleucine to norvaline led to a more 
favorable enthalpy of binding and less favorable entropy of binding when ligands with 
leucine and valine residues at the pY+3 site led to a decrease in binding affinity and more 
favorable entropy of binding will be interesting.  If X-ray structures indicate the hypothesis 
that the β-methyl group of isoleucine prevents deeper insertion of the ligand into the 
binding pocket is plausible, then preparing other ligands with linear alkyl chains at the 
pY+3 amino acid side chain may lead to an even more favorable ΔH° of binding compared 
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to ligand 25.  Of course, the more favorable ΔH° of binding of ligand 25 was offset by a 
less favorable ΔS° of binding.  Nonetheless, this experiment could at least inform how side 
chain length at the pY+3 site influences the thermodynamics of binding.  A crystal structure 
of Src SH2-bound ligand 24 will also shed light on how altering the backbone geometry of 
the ligand by introducing the cyclopropane affected the binding conformation and what 
binding contacts are present that led to a nearly identical ΔH° of binding as ligand 25.  
Molecular dynamics simulations could also prove valuable in analyzing the ligands in their 
solution state.  The result that ligand 24 is a less potent ligand than ligand 25 could be 
potentially explained by analyzing their solution state energies, as previously mentioned. 
Working toward understanding the energetics of protein-ligand interactions is a 
difficult, but important endeavor.  Studies in this arena of science illuminate the 
complexities of protein-ligand interactions that are key to innumerable biological 
processes.  The more we learn about these interactions, the more we can begin to predict 
the effects of structure on energetics of binding.  The emergence of better models for 
predicting the effects of small molecule structure on binding will have tremendous impacts 
in science, but there remains much to study and investigate in the field of protein-ligand 
interactions.  
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Chapter 3:  Methods and Experimental Procedures 
3.1 ORGANIC SYNTHESIS 
3.1.1 General 
Solvents and reagents were reagent grade and were used without purification, 
unless otherwise noted.  Tetrahydrofuran (THF) and diethyl ether (Et2O) were dried by 
passage through two columns of activated neutral alumina.  Methanol (MeOH) and N, N-
dimethylformamide (DMF) were dried by passage through two columns of activated 
molecular sieves.  Toluene was dried by passage through a column of activated neutral 
alumina followed by passage through a column of Q5 reactant.  Reactions involving air- 
or moisture-sensitive reagents or intermediates were performed under either an atmosphere 
of argon or nitrogen.  All glassware used in the reactions was either flame dried or oven 
dried prior to use.  Removal of solvent or volatiles was performed using a rotary evaporator.  
Thin layer chromatography (TLC) was performed on glass-backed pre-coated silica gel 
plates (0.25 mm thick with 60 F254 indicator) and was visualized by one or more of the 
following:  UV (254 nm) irradiation, treatment with aqueous potassium permanganate 
(KMnO4) followed by heating, or treatment with aqueous ceric ammonium molybdate 
(CAM) followed by heating.  Flash chromatography was performed with the indicated 
solvents using silica gel (Silicycle, 40-63 μm, 60 Å).  Reverse phase HPLC was performed 
using a binary solvent system, where solvent A was 0.1% aqueous trifluoroacetic acid 
(TFA) and solvent B was 0.1% TFA in acetonitrile, with a C18 column (10 mm particle 
size, 300 Å pore size), 22 mm diameter x 250 mm (flow rate of 5 mL/min).  Proton (1H) 
and carbon (13C) nuclear magnetic resonance (NMR) were obtained as solutions in the 
indicated solvents using either a 400 MHz or 600 MHz spectrometer.  Chemical shifts are 
reported in parts per million (ppm, δ) downfield from TMS (δ = 0.00 ppm) and referenced 
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relative to the 7.24 ppm resonance of CDCl3 or the center of the 2.50 ppm quintet resonance 
of DMSO-d6 for 
1H and relative to the center of the triplet of CDCl3 at 77.0 ppm or the 
center of the 39.5 ppm septet resonance of DMSO-d6 for 
13C.  Coupling constants are 
reported in hertz (Hz).  Splitting patterns are designated as: s = singlet; d = doublet; dd = 
doublet of doublet; ddd = doublet of doublet of doublets; t = triplet; q = quartet; p = 
pentuplet; m = multiplet; comp = overlapping multiplets of non-magnetically equivalent 
protons; br = broad; app = apparent. 
Schöllkopf auxiliary 50 was prepared according to the procedure reported by Chen, 
et al.65  Compound 50 was used to prepare the ethyl ester of allo-coronamic acid (28) 
according to the procedure reported by Groth, et al.47  Tetrapeptide 25 was prepared 
according to the procedure reported by Bonaparte.45 
3.1.2 Compounds 
 
 Methyl 2-benzyloxycarbonylamino-2-(dimethoxyphosphoryl)acetate 32. 
(CAF0083).  A mixture of benzyl carbamate (1.19 g, 7.86 mmol), 37 (0.90 g, 10.22 mmol), 
and acetyl chloride (1.95 g, 24.80 mmol) in toluene (135 mL, 0.1M) was stirred at 60 °C 
for 14 h.  The temperature was then increased to 75 °C, and trimethyl phosphite (2.44 g, 
19.69 mmol) was added dropwise.  The reaction was stirred for 3 h.  The mixture was 
concentrated under reduced pressure, and the residue was dissolved in EtOAc (25 mL) and 
washed with a saturated solution of NaHCO3 (25 mL).  The organic layer was dried 
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(MgSO4), filtered, and concentrated to provide 32 as a light yellow solid. (1.56 g, 60% 
yield).  1H and 13C NMR data were consistent with the reported literature values.31 
 
 Methyl (1S,2R)-1-(((benzyloxy)carbonyl)amino)-2-((S)-2,2-dimethyl-1,3-
dioxolan-4-yl)cyclopropane-1-carboxylate 41. (CAF0083).  Compound 40 (0.74 g, 2.21 
mmol) was stirred in DCM (22 mL, 0.1M) at -10 °C.  Neat Et2Zn (1.37 g, 11.06 mmol) 
was added dropwise to the solution, and diiodomethane (2.96 g, 11.06 mmol) was added 
immediately.  The solution was warmed to room temperature over 3 h and then stirred an 
additional 3 h.  The reaction was cooled to 0 °C and was quenched by the addition of a 
saturated solution of NH4Cl (6 mL).  The mixture was diluted with ether (10 mL), and a 
small amount of 0.1 M HCl (aq) (0.5 mL) was added.  The layers were separated, then the 
organic layer was sequentially washed with saturated Na2SO3 (10 mL), saturated NaHCO3 
(10 mL), and brine (10 mL).  The organic layer was dried (MgSO4) and then concentrated 
under reduced pressure.  The crude yield of 0.77 g (99% mass conversion) was sufficiently 
pure to use in the next step.  1H and 13C NMR data were consistent with the reported 
literature values.24 
 
General procedure for peptide coupling.  Preparation of 55, 57, 60. 
 A solution of N-Methylmorpholine (NMM) (0.307 g, 0.33 mL, 3.03 mmol), N-
protected amino acid (0.708 mmol), EDCI•HCl (0.194 g, 1.011 mmol), and OxymaPure 
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(0.144 g, 1.011 mmol) was stirred in DMF (11.2 mL) at room temperature for 30 min.  A 
solution of the C-protected amino acid (0.674 mmol) in DMF (7.5 mL) was added in one 
portion, and the mixture was stirred for 15 h.  The mixture was concentrated under vacuum.  
Saturated NaHCO3 (aq) (30 mL) was added then the aqueous phase was extracted with 
DCM (3 x 20 mL).  The combined organic layers were washed with saturated NaHCO3 (1 
x 20 mL), 1 M HCl (3 x 20 mL), brine (1 x 30 mL), dried (MgSO4), and concentrated under 
reduced pressure.  The crude product was purified by flash column chromatography. 
 
 
Ethyl (1S,2R)-1-((S)-5-(benzyloxy)-2-((tert-butoxycarbonyl)amino)-5-
oxopentanamido)-2-ethylcyclopropane-1-carboxylate 55. (CAF0280).  Prepared 
according to the general procedure.  The crude material was purified by flash 
chromatography eluting with hexanes:EtOAc (2:1) to provide 71 mg (51%) as a white 
solid.  1H NMR (400 MHz, CDCl3) δ 7.37-7.29 (comp, 5 H), 6.69 (br. s, 1 H), 5.29 (m, 
1H), 5.14 (s, 2 H), 4.20 (m, 1 H), 4.10 (q, J = 7.1 Hz, 2 H), 2.61 (comp, 2 H), 2.18 (m, 1 
H), 1.95 (m, 1 H), 1.76-1.51 (comp, 4 H), 1.42 (s, 9 H), 1.19 (t, J = 7.1 Hz, 3 H, C1-H), 
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1.02 (t, J = 7.3 Hz, 3 H) 0.84 (comp, 1 H); 13C NMR (400 MHz, CDCl3) δ 173.4, 172.8, 
172.2, 135.7, 128.6, 128.2, 66.6, 61.3, 37.5, 30.4, 29.8, 28.3, 28.1, 22.9, 21.7, 14.1, 13.4; 
Mass spectrum (ESI+) m/z = 499.2429 [C25H36N2O7 (M + Na) requires 499.2415]. 
NMR Assignments: 1H NMR (400 MHz, CDCl3) δ 7.37-7.29 (comp, 5 H, CAr-
H), 6.69 (br. s, 1 H, amide N-H), 5.29 (m, 1H, carbamate N-H), 5.14 (s, 2 H, C14-H), 4.20 
(m, 1 H, C10-H), 4.10 (q, J = 7.1 Hz, 2 H, C2-H), 2.61 (comp, 2 H, C12-H), 2.18 (m, 1 H, 
C11-H), 1.95 (m, 1 H, C11-H), 1.76-1.51 (comp, 4 H, C5-H and C7-H), 1.42 (s, 9 H, C21-
H), 1.19 (t, J = 7.1 Hz, 3 H, C1-H), 1.02 (t, J = 7.3 Hz, 3 H, C8-H) 0.84 (m, 1 H, C6-H); 
13C NMR (400 MHz, CDCl3) δ 173.4 (C3 or C9 or C13), 172.8 (C3 or C9 or C13), 172.2 
(C3 or C9 or C13), 135.7 (C15), 128.6 (CAr), 128.2 (CAr), 66.6 (C14), 61.3 (C10), 37.5 
(C2), 30.4 (C12), 29.8 (C6), 28.3 (C21), 28.1 (C5), 22.9 (C11), 21.7 (C7), 14.1 (C1), 13.4 
(C8). 
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Ethyl (1S,2R)-1-((S)-5-(benzyloxy)-2-((S)-5-(benzyloxy)-2-((tert-
butoxycarbonyl)amino)-5-oxopentanamido)-5-oxopentanamido)-2-
ethylcyclopropane-1-carboxylate 57. (CAF0300).  Prepared according to the general 
procedure.  The crude material was purified by flash chromatography eluting with 
hexanes:EtOAc (1:1) to provide 108 mg (61%) as a white solid.  1H NMR (400 MHz, 
CDCl3) δ 7.39-7.30 (comp, 10 H), 5.20-5.07 (comp, 4 H), 4.47 (m, 1 H), 4.07 (comp, 3 H), 
2.75-2.41 (comp, 4 H), 2.22-1.84 (comp, 4 H), 1.82-1.52 (comp, 4 H), 1.42, (s, 9 H), 1.17 
(t, J = 7.1 Hz, 3 H), 1.01 (t, J = 7.3 Hz, 3 H), 0.89 (m, 1 H); 13C NMR (400 MHz, CDCl3) 
δ 174.3, 173.2, 172.2, 172.0, 171.6, 156.1, 135.6, 135.6, 128.6, 128.3, 128.3, 128.2, 80.6, 
66.7, 66.7, 61.2, 55.0, 52.5, 37.7, 30.7, 30.4, 29.9, 28.3, 26.9, 22.3, 22.3, 21.5, 14.1, 13.5; 
Mass spectrum (ESI+) m/z = 696.3503 [C37H49N3O10 (M + H) requires 696.3491]. 
 NMR Assignments: 1H NMR (400 MHz, CDCl3) δ 7.39-7.30 (comp, 10 H, CAr-
H), 5.20-5.07 (comp, 4 H, C14-H, C24-H), 4.47 (m, 1 H, C10-H), 4.07 (comp, 3 H, C2-H, 
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C20-H), 2.75-2.41 (comp, 4 H, C12-H, C22-H), 2.22-1.84 (comp, 4 H, C11-H, C21-H), 
1.82-1.52 (comp, 4 H, C5-H and C7-H), 1.42, (s, 9 H, C31-H), 1.17 (t, J = 7.1 Hz, 3 H, C1-
H), 1.01 (t, J = 7.3 Hz, 3 H, C8-H) 0.89 (m, 1 H, C6-H); 13C NMR (400 MHz, CDCl3) δ 
174.3 (C3 or C9 or C13 or C19 or C23), 173.2 (C3 or C9 or C13 or C19 or C23), 172.2 
(C3 or C9 or C13 or C19 or C23), 172.0 (C3 or C9 or C13 or C19 or C23), 171.6 (C3 or 
C9 or C13 or C19 or C23), 156.1 (C29), 135.6 (C15 or C25), 135.6 (C15 or C25), 128.6 
(CAr), 128.3 (CAr), 128.3 (CAr), 128.2 (CAr), 80.6 (C30), 66.7 (C14 or C24), 66.7 (C14 
or C24), 61.2 (C10), 55.0 (C20), 52.5 (C4), 37.7 (C2), 30.7 (C12 or C22), 30.4 (C12 or 
C22), 29.9 (C6), 28.3 (C31), 26.9 (C5), 22.36 (C11 or C21), 22.3 (C11 or C21), 21.5 (C7), 
14.1 (C1), 13.5 (C8). 
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Ethyl (1S,2R)-1-((5S,8S,11S)-8,11-bis(3-(benzyloxy)-3-oxopropyl)-5-(4-
((bis(benzyloxy)phosphoryl)oxy)benzyl)-3,6,9-trioxo-1-phenyl-2-oxa-4,7,10-
triazadodecan-12-amido)-2-ethylcyclopropane-1-carboxylate 60. (CAF1023).  
Prepared according to the general procedure.  The crude material was purified by flash 
chromatography eluting with hexanes:EtOAc (1:2) to provide 69 mg (55%) as a white 
solid.  1H NMR (400 MHz, CDCl3) δ 7.35-7.28 (comp, 20 H), 7.25 (comp, 2 H), 7.05 
(comp, 2 H), 5.12-5.00 (comp, 4 H), 4.46-4.25 (comp, 3 H), 4.10 (q, J = 7.1 Hz, 2 H), 3.06 
(m, 1 H), 2.88 (m, 1 H), 2.68-2.32 (comp, 4 H), 2.29-1.87 (comp, 4 H), 1.79-1.51 (comp, 
4 H), 1.15 (t, J = 7.1 Hz, 3 H), 1.00 (t, J = 7.3 Hz, 3 H) 0.87 (m, 1 H); 13C NMR (400 MHz, 
CDCl3) δ 174.1, 173.5, 172.3, 172.2, 171.8, 170.6, 156.5, 135.8, 135.7, 135.4, 135.3, 130.4, 
128.6, 128.5, 128.5, 128.4, 128.3, 128.2, 128.2, 128.2, 128.1, 128.00, 127.95, 120.4, 70.0, 
67.4, 66.8, 66.5, 61.2, 56.6, 52.9, 37.7, 30.7, 30.6, 30.0, 26.9, 26.3, 22.4, 22.4, 21.6, 14.1, 
13.6; Mass spectrum (ESI+) m/z = 1175.4401 [C63H69N4O15 (M + Na) requires 1175.4389]. 
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 NMR Assignments: 1H NMR (400 MHz, CDCl3) δ 7.35-7.28 (comp, 20 H, CAr-
H), 7.25 (comp, 2 H, C33-H or C34-H), 7.05 (comp, 2 H, C33-H or C34-H), 5.12-5.00 
(comp, 4 H, C14-H, C24-H, C36-H,  C42-H), 4.46-4.25 (comp, 3 H, C10-H, C20-H,  C30-
H), 4.10 (q, J = 7.1 Hz, 2 H, C2-H), 3.06 (m, 1 H, C31-H), 2.88 (m, 1 H, C31-H), 2.68-
2.32 (comp, 4 H, C12-H, C22-H), 2.29-1.87 (comp, 4 H, C11-H, C21-H), 1.79-1.51 (comp, 
4 H, C5-H and C7-H), 1.15 (t, J = 7.1 Hz, 3 H, C1-H), 1.00 (t, J = 7.3 Hz, 3 H, C8-H) 0.87 
(m, 1 H, C6-H); 13C NMR (400 MHz, CDCl3) δ 174.1 (C3 or C9 or C13 or C19 or C23 or 
C29), 173.5 (C3 or C9 or C13 or C19 or C23 or C29), 172.3 (C3 or C9 or C13 or C19 or 
C23 or C29), 172.2 (C3 or C9 or C13 or C19 or C23 or C29), 171.8 (C3 or C9 or C13 or 
C19 or C23 or C29), 170.6 (C3 or C9 or C13 or C19 or C23 or C29), 156.5 (C46), 135.75 
(C15 or C25 or C42 or C37), 135.7 (C15 or C25 or C42 or C37), 135.4, (C15 or C25 or 
C42 or C37), 135.3 (C15 or C25 or C42 or C37), 130.4 (C32), 128.6 (CAr), 128.5 (CAr), 
128.5 (CAr), 128.4 (CAr), 128.3 (CAr), 128.2 (CAr), 128.2 (CAr), 128.2 (CAr), 128.1 
(CAr), 128.00 (CAr), 127.95 (CAr), 120.4 (C35), 70.0 (C30), 67.4 (C14 or C24 or C41 or 
C36), 66.8 (C14 or C24 or C41 or C36), 66.5 (C14 or C24 or C41 or C36), 61.2 (C10), 
56.6 (C20), 52.9 (C4), 37.7 (C2), 30.7 (C12 or C22), 30.6 (C12 or C22), 30.0 (C6), 26.9 
(C5), 26.3 (C31), 22.4 (C11 or C21), 22.4 (C11 or C21), 21.6 (C7), 14.1 (C1), 13.6 (C8). 
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(S)-5-(Benzyloxy)-1-(((1S,2R)-1-(ethoxycarbonyl)-2-ethylcyclopropyl)amino)-1,5-
dioxopentan-2-aminium trifluoroacetate 56. (CAF0304).  Trifluoroacetic acid (TFA) 
(0.995 g, 0.65 mL, 8.729 mmol) was added to a solution of dipeptide 55 (0.104 g, 0.218 
mmol) in DCM (2.2 mL) at room temperature and was stirred for 4 h.  The solution was 
concentrated under reduced pressure, and then the residue was azeotroped with toluene (3 
x 15 mL) to give 0.106 g (quant. yield) of crude 56 as a sticky yellow resin that was used 
without further purification.  1H NMR (400 MHz, CDCl3) δ 7.37-7.29 (comp, 5 H), 5.09 
(comp, 2 H), 4.65 (br, 1 H), 4.06 (q, J = 7.1 Hz, 2 H), 2.53 (t, J = 7.4 Hz, 2 H), 2.09 (m, 1 
H), 1.87 (m, 1 H), 1.70-1.52 (comp, 4 H, C5-H and C7-H), 1.19 (t, J = 7.1 Hz, 3 H, C1-H), 
1.00 (t, J = 7.3 Hz, 3 H, C8-H) 0.85 (comp, 1 H, C6-H); Mass spectrum (ESI+) m/z = 
377.2085 [C20H28N2O5 (M + H) requires 377.2071]. 
 NMR Assignments:  1H NMR (400 MHz, CDCl3) δ 7.37-7.29 (comp, 5 H, CAr-
H), 5.09 (comp, 2 H, C14-H), 4.65 (br, 1 H, C10-H), 4.06 (q, J = 7.1 Hz, 2 H, C2-H), 2.53 
(t, J = 7.4 Hz, 2 H, C12-H), 2.09 (m, 1 H, C11-H), 1.87 (m, 1 H, C11-H), 1.70-1.52 (comp, 
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4 H, C5-H and C7-H), 1.19 (t, J = 7.1 Hz, 3 H, C1-H), 1.00 (t, J = 7. Hz, 3 H, C8-H) 0.85 
(comp, 1 H, C6-H). 
 
 
(S)-5-(Benzyloxy)-1-(((S)-5-(benzyloxy)-1-(((1S,2R)-1-(ethoxycarbonyl)-2-
ethylcyclopropyl)amino)-1,5-dioxopentan-2-yl)amino)-1,5-dioxopentan-2-aminium 
trifluoroacetate 58. (CAF1022).  TFA (0.56 g, 0.37 mL, 4.944 mmol) was added to a 
solution of tripeptide 57 (86 mg, 0.124 mmol) in DCM (1.3 mL) at room temperature and 
was stirred for 4 h.  The solution was concentrated under reduced pressure, and then the 
residue was azeotroped with toluene (3 x 15 mL) to give 73 mg (quant. yield) of crude 58 
as a yellow oil that was used without further purification.  1H NMR (400 MHz, CDCl3) δ 
7.39-7.29 (comp, 10 H), 5.17-5.06 (comp, 4 H), 4.45 (m, 1 H), 4.09 (q, J = 7.1 Hz, 2 H), 
3.38 (m, 1 H), 2.68-2.42 (comp, 4 H), 2.30-1.78 (comp, 4 H), 1.71-1.50 (comp, 4 H), 1.18 
(t, J = 7.1 Hz, 3 H), 1.01 (t, J = 7.3 Hz, 3 H) 0.82 (m, 1 H; 13C NMR (400 MHz, CDCl3) δ 
174.8, 173.3, 173.1, 172.4, 172.2, 135.7, 135.7, 128.6, 128.3, 66.6, 66.5, 61.3, 54.5, 51.8, 
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37.6, 30.7, 30.1, 29.7, 27.6, 22.8, 22.8, 21.7, 14.1, 13.5; Mass spectrum (ESI+) m/z = 
618.2802 [C32H41N3O8 (M + Na) requires 618.2786]. 
 NMR Assignments: 1H NMR (400 MHz, CDCl3) δ 7.39-7.29 (comp, 10 H, CAr-
H), 5.17-5.06 (comp, 4 H, C14-H, C24-H), 4.45 (m, 1 H, C10-H), 4.09 (q, J = 7.1 Hz, 2 H, 
C2-H), 3.38 (m, 1 H, C20-H), 2.68-2.42 (comp, 4 H, C12-H, C22-H), 2.30-1.78 (comp, 4 
H, C11-H, C21-H), 1.71-1.50 (comp, 4 H, C5-H and C7-H), 1.18 (t, J = 7.1 Hz, 3 H, C1-
H), 1.01 (t, J = 7. Hz, 3 H, C8-H) 0.82 (m, 1 H, C6-H); 13C NMR (400 MHz, CDCl3) δ 
174.8 (C3 or C9 or C13 or C19 or C23), 173.3 (C3 or C9 or C13 or C19 or C23), 173.1 
(C3 or C9 or C13 or C19 or C23), 172.4 (C3 or C9 or C13 or C19 or C23), 172.2 (C3 or 
C9 or C13 or C19 or C23), 135.7 (C15 or C25), 135.7 (C15 or C25), 128.6 (CAr), 128.3 
(CAr), 66.6 (C14 or C24), 66.5 (C14 or C24), 61.3 (C10), 54.5 (C20), 51.8 (C4), 37.6 (C2), 
30.7 (C12 or C22), 30.1 (C12 or C22), 29.7 (C6), 27.6 (C5), 22.8 (C11 or C21), 22.8 (C11 
or C21), 21.7 (C7), 14.1 (C1), 13.5 (C8). 
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(1S,2R)-1-((S)-2-((S)-2-((S)-2-Acetamido-3-(4-(phosphonooxy)phenyl)propanamido)-
4-carboxybutanamido)-4-carboxybutanamido)-2-ethylcyclopropane-1-carboxylic 
acid 26. (CAF1118). 10% Pd/C (3 mg, 10% wt) was added to a solution of tetrapeptide 60 
(27 mg, 0.023 mmol) in MeOH/H2O (12 mL, 5:1), and the flask was purged three times 
with H2.  The suspension was stirred under H2 (1 atm) for 1.5 h at room temperature.  The 
suspension was filtered through a pad of celite, and the pad was washed with MeOH (5 
mL) and H2O (10 mL).  The filtrate was concentrated under reduced pressure.  The residue 
was dissolved in THF/H2O (5.2 mL, 0.5:4.7) and LiOH•H2O was added (45 mg, 1.063 
mmol) to the solution.  The solution was stirred at room temperature for 24 h, then the 
reaction was concentrated under reduced pressure.  The residue was dissolved in 
dioxane/H2O (0.55 mL, 4:1) and Ac2O (0.214 g, 0.20 mL, 2.10 mmol) was added.  The 
solution was stirred at room temperature for 18 h, then MeOH (1 mL) was added.  The 
reaction was concentrated under reduced pressure.  The crude product was purified by RP 
HPLC with a gradient of 0-30% acetonitrile in H2O over 30 min (12.8 min) and lyophilized 
to provide 2.2 mg (17%) of 26 a white solid. 1H NMR (400 MHz, DMSO-d6) δ 8.11 (m, 1 
H), 8.05 (m, 1 H), 7.95 (m, 1 H), 7.88 (m, 1 H), 6.97 (comp, 4 H), 4.41 (app q, J = 6.8 Hz, 
1 H), 4.20 (m, 1 H), 4.09 (m, 1 H), 2.86-2.73 (comp, 2 H), 2.24 (comp, 2 H), 2.05 (comp, 
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2H), 1.81 (s, 3 H), 1.78-1.64 (comp, 4 H), 1.51-1.43 (comp, 3 H), 1.29 (m, 1 H), 0.95-0.86 
(comp, 4 H); 13C NMR (400 MHz, DMSO-d6) δ 174.9, 174.6, 174.5, 172.9, 172.8, 171.3, 
170.1, 153.0, 130.4, 130.0, 120.0, 54.6, 52.74, 52.72, 52.5, 37.0, 30.9, 30.7, 29.4, 28.6, 
27.7, 27.3, 22.9, 21.6, 14.1; Mass spectrum (ESI+) m/z = 695.1945 [C27H37N4O14 (M + Na) 
requires 695.1936]. 
 NMR Assignments: 1H NMR (400 MHz, DMSO-d6) δ 8.11 (m, 1 H, N-H), 8.05 
(m, 1 H, N-H), 7.95 (m, 1 H, N-H), 7.88 (m, 1 HN-H), 6.97 (comp, 4 H, C21-H and C22-
H), 4.41 (app q, J = 6.8 Hz, 1 H, C18-H), 4.20 (m, 1 H, C8-H), 4.09 (m, 1 H, C13-H), 2.86-
2.73 (comp, 2 H, C19-H), 2.24 (comp, 2 H, C10-H or C-15 H), 2.05 (comp, 2H, C10-H or 
C15-H), 1.81 (s, 3 H, C25-H), 1.78-1.64 (comp, 4 H, C9-H and C14-H), 1.51-1.43 (comp, 
3 H, C4-H and C5-H), 1.29 (m, 1 H, C3-H), 0.95-0.86 (comp, 4 H, C3-H and C6-H); 13C 
NMR (400 MHz, DMSO-d6) δ 174.9 (C1 or C11 or C16), 174.6 (C1 or C11 or C16), 174.5 
(C1 or C11 or C16), 172.9 (C7 or C12 or C17 or C24), 172.8 (C7 or C12 or C17 or C24), 
171.3 (C7 or C12 or C17 or C24), 170.1 (C7 or C12 or C17 or C24), 153.0 (C23), 130.4 
(C21), 130.0 (C22), 120.0 (C20), 54.6 (C18), 52.7 (C8 or C13), 52.7 (C8 or C13), 52.5 
(C2), 37.0 (C19), 30.9 (C10 or C15), 30.7 (C10 or C15), 29.4 (C4), 28.6 (C3), 27.7 (C9 or 
14), 27.3 (C9 or 14), 22.9 (C25), 21.6 (C5), 14.1 (C6). 
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3.2 BIOLOGICAL MATERIALS AND METHODS 
3.2.1 Preparation of Src SH2 
 A 30 mL culture of LB/amp (100 μg/mL) was inoculated with a single colony of E. 
coli bearing the Src SH2 domain plasmid overnight at 37 °C in a shaker at 225 rpm.  The 
culture was used to inoculate a larger culture (1 L) of LB/amp (100 μg/mL) which was 
incubated at 30 °C in a shaker at 75 rpm until an OD600 value of 0.8-1.0 was reached.  
Expression of protein was induced by adding IPTG (0.1 mM final concentration) and the 
cultures continued to incubate at 30 °C for an additional 15-16 h.  The cultures were 
centrifuged at 8,000xg at 4 °C for 15 min.  The supernatant was decanted and the cell 
pellets were stored at -80 °C until they were to be lysed. 
 One pellet was resuspended in 30 mL lysis buffer (20 mM sodium citrate, 1 mM 
EDTA, 0.1 mM PMSF, 0.1% v/v β-mercaptoethanol (BME), pH = 6.0 ± 0.05).  The cells 
were lysed by probe sonication on ice for 2 min (2 sec pulse, 8 sec rest) and then centrifuged 
at 10,000xg at 4 °C for 45 min.  The supernatant was reserved and the pellet was discarded 
The supernatant (~35 mL) was loaded onto a 15 mL SP-sepharose ion exchange 
column equilibrated with Buffer A (20 mM sodium citrate, 1 mM EDTA, 0.1% v/v β-
mercaptoethanol (BME), pH = 6.0 ± 0.05) (3 mL/min).  The lysate was eluted with Buffer 
A (75 mL), then eluted with a gradient of Buffer A and Buffer B (20 mM sodium citrate, 
1 mM EDTA, 0.1% v/v β-mercaptoethanol (BME), pH = 6.0 ± 0.05) (0%-50% Buffer B 
over 100 mL).  The column was washed with 100% Buffer B (75 mL), and then washed 
with Buffer A (75 mL).  The fractions containing Src SH2 were concentrated to a volume 
of ~0.7-1.0 mL. 
The concentrate from the previous step was loaded onto a 100 mL Size Exclusion 
column and eluted with Buffer C (20 mM MES, 5 mM DTT, 1 mM EDTA, 50 mM NaCl 
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20 mM sodium citrate, 1 mM EDTA, 0.1% v/v β-mercaptoethanol (BME), pH = 6.0 ± 0.05) 
(0.5 mL/min).  The fractions containing Src SH2 were dialyzed using 1000-3000 MW 
cutoff dialysis tubing in HEPES buffer (20 mM HEPES, 1 mM EDTA, 100 mM NaCl, 1 
mM BME, pH = 7.3 ± 0.05) (2 L) for 24 h.  The dialysis buffer was replaced with a fresh 
solution of the same HEPES buffer and the protein solution was dialyzed for 24 h.  Protein 
concentration was determined by using UV-Vis spectroscopy using the extinction 
coefficient for the Src SH2 domain (ε280 = 14,700 M-1cm-1).35  Concentrations of 60-80 μM 
were acceptable for ITC experiments. 
3.2.2 Isothermal Titration Calorimetry 
Ligand solutions were prepared to 15x concentration of protein by weighing the 
solids on an analytical balance and then dissolving in 996 μL HEPES buffer.  NaOH (aq) 
was added to adjust the pH to 7.3 ± 0.05.  The ligand and protein solutions were filtered 
through a 0.2 μm sterile filter and degassed for 15 min prior to the ITC experiment. 
Plots were obtained for the titration of Src SH2 domain with the indicated ligands 
in HEPES buffer at 25 °C.  Titration data was obtained from 1 x 2 μL and 39 x 8 μL 
injections of ligand, resulting in peaks corresponding to the heats of complexation (μcal/s).   
Integrated ITC data provides the heat of binding per mol of injected ligand.  The 
data were corrected by subtracting the heat of addition of the final injection, at which point 
all protein is complexed and the injection represents a blank titration.  The trace was 
determined by applying a nonlinear least squares fit to determine binding stoichiometry n, 
Ka, and ΔH°.  The values for ΔG° and ΔS° were calculated from Ka and ΔH°.  Raw values 
of 0.9 < n < 1.2 were considered acceptable, and n was corrected to 1.000 for the reported 
data.   
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Average (from 4 titrations) 
 
Ka = 4.0 (± 0.3) 10
6 M-1 
ΔG° -9.00 ± 0.05 kcal/mol 
ΔH° = -5.36 ± 0.34 kcal/mol 
ΔS° = -3.64 ± 0.66 kcal/mol 
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